Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kernel
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Ketamine cohort
Adult between the ages of 18 - 65, inclusive at time of enrollment
Primary diagnosis of MDD as defined by DSM-5
Determined by clinic to be eligible for ketamine treatment and agrees to receive ketamine treatment
Agrees to start ketamine treatment in conjunction with study participation to capture pre-treatment measurements accurately
Has not received a ketamine treatment course in the past 12 months
Has not received a TMS treatment course in the past 3 months
Ability to consent for themselves
Fluency in English (speaking and reading)
SPRAVATO cohort
Adult between the ages of 18 - 75, inclusive at time of enrollment
Primary diagnosis of MDD as defined by DSM-5
Determined by clinic to be eligible for SPRAVATO treatment and agrees to receive SPRAVATO treatment
Agrees to start SPRAVATO treatment in conjunction with study participation to capture pre-treatment measurements accurately
Has not received a ketamine or SPRAVATO treatment course in the past 12 months
Has not received a TMS treatment course in the past 3 months
Ability to consent for themselves
Fluency in English (speaking and reading)
TMS cohort
Adult between the ages of 18 - 65, inclusive at time of enrollment
Primary diagnosis of MDD as defined by DSM-5
Determined by clinic to be eligible for TMS treatment and agrees to receive TMS treatment
Agrees to start TMS treatment in conjunction with study participation to capture pre-treatment measurements accurately
Has not received a TMS treatment course in the past 12 months
Has not received a ketamine or SPRAVATO treatment course within the last 3 months
Ability to consent for themselves
Fluency in English (speaking and reading)
Antidepressants cohort
Adult between the ages of 18 - 65, inclusive at time of enrollment
Primary diagnosis of MDD as defined by DSM-5
Determined by clinic to be eligible for antidepressant treatment and agrees to receive antidepressant treatment
Agrees to start antidepressant treatment in conjunction with study participation to capture pre-treatment measurements accurately
Has not taken antidepressants in the past 3 months
Has not received a TMS, SPRAVATO, or ketamine treatment course in the past 3 months
Ability to consent for themselves
Fluency in English (speaking and reading)
You may not be if
Is or may be pregnant (for participant of childbearing potential \[POCBP\]), even if they have been cleared to receive the depression treatment
Unable or unwilling to wear the TD-fNIRS headset
Has had ECT in the past 3 months
Major visual or auditory deficits that would prevent study task completion
Hospitalizations and/or unstable health/medical condition/treatment in the last 30 days
Major medical illnesses and psychiatric conditions including:
* Alzheimer's/Mild Cognitive Impairment
* Parkinson's disease
* Motor neuron diseases
* Multiple Sclerosis
* Brain Tumor
* Stroke
* Encephalitis
* Meningitis
* Epilepsy
* TBI with serious results (coma, unconscious for \>2 hrs, or skull fracture)
* Current serious psychiatric conditions (bipolar disorder, schizophrenia, or psychosis)
Any other clinically significant medical condition or circumstance that, in the opinion of the Investigator, could affect patient safety, preclude evaluation of response, interfere with the ability to comply with study procedures, or prohibit completion of the study
Not an appropriate candidate for the study in the judgment of the investigator(s)
Clareo Health | Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements
